| Autor: |
Hwang, Eunmi, Doolittle, Woo Kyung Lee, Zhu, Yuelin Jack, Zhu, Xuguang, Zhao, Li, Yu, Yanlin, Cheng, Sheue-yann |
| Zdroj: |
Oncogene; October 2023, Vol. 42 Issue: 41 p3075-3086, 12p |
| Abstrakt: |
Thyroid hormone receptor α1 (TRα1) mediates the genomic actions of thyroid hormone (T3). The biology of TRα1 in growth and development has been well studied, but the functional role of TRα1 in cancers remains to be elucidated. Analysis of the human thyroid cancer database of The Cancer Genome Atlas (TCGA) showed that THRAgene expression is lost in highly dedifferentiated anaplastic thyroid cancer (ATC). We, therefore, explored the effects of TRα1 on the progression of ATC. We stably expressed TRα1 in two human ATC cell lines, THJ-11T (11T-TRα1 #2, #7, and #8) and THJ-16T (16T-TRα1 #3, #4, and #8) cells. We found that the expressed TRα1 inhibited ATC cell proliferation and induced apoptosis. TCGA data showed that THRAgene expression was best correlated with the paired box gene 8 (PAX8). Consistently, we found that the PAX8expression was barely detectable in parental 11T and 16T cells. However, PAX8gene expression was elevated in 11T- and 16T-TRα1-expressing cells at the mRNA and protein levels. Using various molecular analyses, we found that TRα1 directly regulated the expression of the PAX8gene. Single-cell transcriptomic analyses (scRNA-seq) demonstrated that TRα1 functions as a transcription factor through multiple signaling pathways to suppress tumor growth. Importantly, scRNA-seq analysis showed that TRα1-induced PAX8, via its transcription program, shifts the cell landscape of ATC toward a differentiated state. The present studies suggest that TRα1 is a newly identified regulator of thyroid differentiation and could be considered as a potential therapeutic target to improve the outcome of ATC patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink